Sequenom recruited former Amgen CEO Harry Hixson to its board, the company said Jan. 14. Hixson is currently chairman and CEO of privately held drug firm Elitra Pharmaceuticals.
Pyrosequencing named Mats-Olof Wallin CFO, capping a broad restructuring begun in October.
Wallin, 51, is currently CFO of Ortivus, a Swedish medical technology company. He will oversee Pyrosequencing’s financings in Sweden and in the US.
Hyseq and Variagenics have named six board members and a chairman to oversee the new — and still unnamed — company set to emerge Jan. 28 [see accompanying story, page 3]. From the Hyseq side, Chairman George Rathmann, 75, will retain his title at the new firm. He will be joined on the board by Hyseq compatriots Ted Love, 43; Richard Brewer, 51; and Mary Pendergast, 52. Variagenics, meantime, will chip in Phillipe Chambon, 44; Jean-Francois Formela, 46; and Martin Vogelbaum, 39.